13
Participants
Start Date
February 4, 2019
Primary Completion Date
October 27, 2020
Study Completion Date
October 27, 2020
Loncastuximab Tesirine and Durvalumab
intravenous infusion
Icahm School of Medicine at Mount Sinai, New York
Hospital General Universitario Gregorio Marañon Pabellón de Oncología, Madrid
Hospital Universitario Fundación Jiménez Díaz Unidad de Limfomas Servicio de Hematologia, Madrid
University of Florida Health Shands Cancer Hospital, Gainesville
University of Miami - Sylvester Comprehensive Cancer Center, Miami
University of Alabama at Birmingham, Birmingham
Hospital Universitario Virgen Macarena Servicio Oncologia Medica, Seville
Hospital Universitario Virgen Del Rocio, Seville
Baylor University Medical Center, Dallas
Baylor Scott & White Medical Center - Temple, Temple
Joe Arrington Cancer Research and Treatment Center, Lubbock
UCH-MHS Memorial Hospital Centeral, Colorado Springs
Rutgers Cancer Institute of New Jersey, New Brunswick
Hospital Clinic de Barcelona, Barcelona
Lead Sponsor
ADC Therapeutics S.A.
INDUSTRY